Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 11, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director share transactions rather than a financial performance report.
Material Changes
The only material change disclosed is a reduction in the shareholding of Dr. MM Slaoui, a Director of the Company.
- Transaction: Vesting of 2,224.96 Ordinary shares under the GlaxoSmithKline Deferred Investment Award on August 1, 2006.
- Payment: Dr. Slaoui received a payment equivalent to GBP 14.71 per share on August 11, 2006.
- Resulting Interest: Dr. Slaoui's total interest decreased by 2,224.96 shares to a total of 36,807.96 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to Disclosure Rule 3.1.4R(1)(b) regarding director notifications.
Investor Verification Points
- Verify the current shareholding balance of Dr. MM Slaoui (36,807.96 shares) against subsequent filings.
- Confirm the vesting terms and payment mechanics of the GlaxoSmithKline Deferred Investment Award.
- Note that this filing contains no operational or financial performance data for the period.